Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study | National Business

PRINCETON, N.J.--(BUSINESS WIRE)--Sep 9, 2023--

Related Keywords

Italy ,Milan ,Lombardia ,United States ,American ,Jonathan Sadeh ,Tameraj Corte ,Bristol Myers Squibb ,Exchange Commission ,European Respiratory Society ,Youtube ,Immunology Development ,Department Of Respiratory Medicine ,International Congress ,Linkedin ,Instagram ,Facebook ,Twitter ,American Thoracic Society ,Myers Squibb ,Abstracts Leading ,Respiratory Medicine Trials ,Professor Tamera ,Consultant Respiratory Physician ,Interstitial Lung Disease ,Respiratory Medicine ,Royal Prince Alfred Hospital ,Bristol Myers ,International Conference ,Pioneering Paths Forward ,Transform Patient ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Business Wire ,National Business ,